India and the US Hold the 2nd Drug Policy Executive Working Group Meeting: Joint Action Against New Drug Threats
The Narcotics Control Bureau (NCB), India's central drug law agency, hosted the 2nd India-United States Drug Policy Executive Working Group Meeting on 2-3 November 2026.
The two countries promised to act together against emerging drug threats, such as synthetic drugs (drugs made from chemicals in labs) and the misuse of ordinary chemicals to make them.
The group was set up under the US-India Drug Policy Framework for the 21st Century, a Memorandum of Understanding (MoU) signed in September 2024. Its first (inaugural) meeting was held in Washington, D.C., on 20-21 January 2026.
Earlier rounds of talks have focused on stopping drug trafficking, stopping the diversion of precursor chemicals, countering synthetic opioids and the misuse of digital platforms, while not disturbing legitimate trade in medicines and chemicals.
India-US Counter-Narcotics Cooperation
India-US counter-narcotics cooperation is the set of agreements and regular meetings through which the two countries work together against drug trafficking. It covers sharing intelligence, joint action against drug networks, control of precursor chemicals, safe medicine supply chains, and treatment of people who use drugs. India matters to the US because it is a major maker of medicines and chemicals. The US matters to India because of its intelligence reach and experience against global drug cartels.
The 2nd Executive Working Group meeting is the latest step under the 2024 framework. It moves the partnership from broad promises to regular senior-level reviews of joint action against new drug threats.
Precursor Chemicals and Synthetic Drug Control
Precursor chemicals are ordinary industrial chemicals that are needed to make illegal drugs. Most of them have honest uses in medicines, paints, plastics, perfumes or dyes. But in the wrong hands, the same chemical becomes a key ingredient for heroin, methamphetamine or fentanyl. Precursor control means tracking who makes, sells and buys these chemicals, so they are not diverted to illegal drug labs, without blocking honest trade.
"Emerging drug threats" largely means synthetic drugs made from precursor chemicals. Because India has a large chemical and pharmaceutical industry, stopping diversion of these chemicals is a central part of its cooperation with the US.
Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985
The Narcotic Drugs and Psychotropic Substances Act, 1985, usually called the NDPS Act, is India's main law against drugs. It decides which drugs are controlled, who may grow, make, sell or use them, and how heavily people are punished for breaking the rules. It also allows some controlled drugs to be used for medical and scientific purposes. Punishment depends mainly on the quantity of drugs involved: small, intermediate or commercial.
The NCB, which hosted the meeting, draws its powers from the NDPS Act. Commitments made with the US, such as tracking precursor chemicals, are carried out in India through this law.
- 2nd India-US Drug Policy Executive Working Group Meeting: 2-3 November 2026, hosted by the NCB
- Inaugural meeting: 20-21 January 2026, Washington, D.C.
- US-India Drug Policy Framework for the 21st Century: MoU signed September 2024; three pillars (counter-narcotics, demand and harm reduction, pharmaceutical supply chain security)
- US lead agency: Office of National Drug Control Policy (ONDCP); Indian lead agency: Narcotics Control Bureau (NCB)
- NCB constituted on 17 March 1986 under Section 4(3) of the NDPS Act, 1985
- 1988 UN Convention: Article 12 controls precursor chemicals (Table I and Table II)